Incidence and Timing of Recurrence After Adjuvant Palbociclib in Completely Resected Retroperitoneal Liposarcoma

Samantha M. Ruff; Madelaine Norris; Gabriel Tinoco; David A. Liebner; Marium Husain; Carlo M. Contreras; Raphael E Pollock; Joal D Beane; Patricia Sarchet; Federica Calore; Giovanni Nigita; Valerie P Grignol

doi:10.1016/j.soi.2026.100247

March 1, 2026Surgical Oncology InsightOpen Access

Incidence and Timing of Recurrence After Adjuvant Palbociclib in Completely Resected Retroperitoneal Liposarcoma

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate recurrence patterns in high-risk retroperitoneal sarcoma patients after adjuvant palbociclib treatment.
Identified patients with no evidence of disease post-resection of retroperitoneal sarcomas
Administered adjuvant palbociclib
Performed bulk RNA sequencing of primary tumor samples
Of 34 patients treated, 8 met inclusion criteria
5 out of 8 developed recurrence after stopping treatment
Most patients (n=7) completed at least 12 months of treatment
Disease-free intervals for 3 non-recurrent patients were 16, 25, and 33 months
Epithelial-mesenchymal transition pathway enriched in recurrence cohort compared to no-recurrence cohort.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

This cohort study evaluates recurrence patterns in high-risk retroperitoneal sarcomas after palbociclib treatment, suggesting potential oncologic benefits.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ruff et al. (2026) studied this question.

synapsesocial.com/papers/69ca134b883daed6ee095333 https://doi.org/10.1016/j.soi.2026.100247

View Full Paper

Ask AI

Bookmark

Share

Incidence and Timing of Recurrence After Adjuvant Palbociclib in Completely Resected Retroperitoneal Liposarcoma

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Incidence and Timing of Recurrence After Adjuvant Palbociclib in Completely Resected Retroperitoneal Liposarcoma

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Keep reading

Keep reading